Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06161220 · ClinicalTrials.gov registry record · Phase 1
A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects
A Phase 1 study, sponsored by Impax Laboratories.
- Completed
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT06161220 is a Phase 1 study that has completed, run by Impax Laboratories. The registered enrollment target is 35 participants.
The verdict
NCT06161220, a Phase 1 study, has completed, sponsored by Impax Laboratories.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
Interventions
- DRUG Placebo
- DRUG Carbidopa capsule
- DRUG Moxifloxacin Tablets, USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2023-10-30 |
| Est. Completion | 2023-12-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06161220
The ClinicalTrials.gov registry entry for NCT06161220 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Impax Laboratories, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06161220 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06161220 about?
NCT06161220 is a clinical study titled "A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy Subjects". The purpose of this trial is to assess the effects of a single supratherapeutic dose of carbidopa on cardiac repolarization relative to placebo in healthy adult subjects.
What is the current status of trial NCT06161220?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2023-10-30. Estimated completion is 2023-12-05.
What interventions are being tested in trial NCT06161220?
The interventions under investigation include: Placebo (DRUG), Carbidopa capsule (DRUG), Moxifloxacin Tablets, USP (DRUG).
Who is sponsoring clinical trial NCT06161220?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.